this number of Cardiovascular Drug and Therapy addresses an important topic of cardiovascular medicine: The current role of ACE-inhibitors for secondary prevention [1]. The authors suggest to reconsider the recommendation of the European Society of Cardiology task force to the use of ACE-inhibitors for secondary prevention labelled as Class I level of evidence A. After the publication of the prevention of events with angiotensinconverting enzyme inhibition (PEACE) trial [2], they believe that the level of evidence is not so strong, therefore the labelling of the recommendation should be Class 1,B. They conclude that ACE-inhibition, presumably irrespective of drug or dose, is not of value in low risk patients with CAD treated with other (statins) proven preventative therapies.
ACE-inhibition for secondary prevention of cardiovascular events - Should we change our recommendation after PEACE?
FERRARI, Roberto
2006
Abstract
this number of Cardiovascular Drug and Therapy addresses an important topic of cardiovascular medicine: The current role of ACE-inhibitors for secondary prevention [1]. The authors suggest to reconsider the recommendation of the European Society of Cardiology task force to the use of ACE-inhibitors for secondary prevention labelled as Class I level of evidence A. After the publication of the prevention of events with angiotensinconverting enzyme inhibition (PEACE) trial [2], they believe that the level of evidence is not so strong, therefore the labelling of the recommendation should be Class 1,B. They conclude that ACE-inhibition, presumably irrespective of drug or dose, is not of value in low risk patients with CAD treated with other (statins) proven preventative therapies.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
